BioGaia signs exclusive agreement in Mongolia
BioGaia has signed an agreement with Monos Pharma LLC for the exclusive rights to sell BioGaia Protectis drops and drops with vitamin D, BioGaia Protectis tablets and tablets with vitamin D, and BioGaia Gastrus in Mongolia. The products will be sold under the BioGaia brand. Launch is planned to the first quarter of 2019.
Monos Pharma LLC was a pioneer when it was established in 1990 as it was one of the first private companies in Mongolia. By 2020 the company will become public through an IPO.
Monos Pharma LLC has its own manufacturing plant where around 80 different pharmaceuticals are produced, whereof 30 are marketed under the company’s own brand.
“It is a pleasure to cooperate with BioGaia. One of the reasons is that BioGaia is the first Swedish company to enter the Mongolian market. We are confident that we will succeed,” says Mrs Erdenechimeg Luvsan, CEO, Monos Pharma LLC.
“I am happy that we are continuing our expansion in the Asian market by launching our products in yet another country,“ says Axel Sjöblad, Managing Director BioGaia.
Latest press releases from BioGaia
2018-04-26 Annual General Meeting of BioGaia
2018-04-25 BioGaia AB – Interim management statement 1 January – 31 March 2018
2018-04-24 New initiative in the fight against antibiotic resistance
For additional information please contact
Axel Sjöblad, Managing Director, BioGaia: +46 8 555 293 00
BioGaia is an innovative Swedish healthcare company that develops, markets and sells probiotic products with documented health benefits. The products are sold through local distribution partners in around 100 countries worldwide. The class B share of the Parent Company BioGaia AB is quoted on the Mid Cap segment of Nasdaq Stockholm. www.biogaia.com
Tags: